Takeda Wants End To Gout Drug Antitrust Case Midtrial

By P.J. D'Annunzio · September 19, 2023, 6:19 PM EDT

Takeda Pharmaceuticals is seeking an early end to an ongoing trial in an antitrust case brought by drug wholesalers over the delayed entry of a generic version of its gout drug...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

VALUE DRUG COMPANY v. TAKEDA PHARMACEUTICALS, U.S.A., INC. et al

Case Number

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Date Filed

August 05, 2021

Recent Articles By P.J.

July 19, 2024
Amazon Gets Tainted Eye Drop Suit Pared Down
June 13, 2024
CVS Dodges Discovery Audit In Generic Drug Collusion Suit
May 17, 2024
Philly Surgeon Settles Sex Bias Case With Jefferson Hospital
May 15, 2024
Former Sandoz Executive Avoids Prison In Price-Fixing Case
May 14, 2024
Hospitals Liable For Failing To Admit Killer, Pa. Justices Told
April 22, 2024
Citing Cozen O'Connor Ties, Pa. Judge Leaves Bias Case
April 15, 2024
Geico Must Arbitrate Fraud Claims Against Chiropractors
April 05, 2024
Surgeon Denied Atty Fees After Erasure of $15M Sex Bias Win
April 02, 2024
3rd Circ. Preview: Black Lung, Back Pay On Tap In April
March 22, 2024
Final OK Sought For Economic Loss Deal In CPAP Recall MDL